Savvy Advisors Inc. Raises Holdings in AbbVie Inc. $ABBV

Savvy Advisors Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 21.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,922 shares of the company’s stock after acquiring an additional 5,236 shares during the quarter. Savvy Advisors Inc.’s holdings in AbbVie were worth $6,928,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie during the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the second quarter worth about $36,000. Delos Wealth Advisors LLC purchased a new position in AbbVie during the 2nd quarter valued at about $39,000. Finally, Cloud Capital Management LLC bought a new position in AbbVie during the 3rd quarter valued at approximately $53,000. Institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record Q4 net sales and upbeat guidance reinforce AbbVie’s diversified growth story (Skyrizi/Rinvoq strength and overall revenue beat), supporting longer-term earnings visibility. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $250 price target following the strong quarter, signaling continued analyst confidence that could support the share price. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: AbbVie’s real‑world migraine (ubrogepant) study could expand market potential for its acute migraine franchise, a constructive long-term revenue opportunity if outcomes are favorable. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Neutral Sentiment: Clinical program update: AbbVie posted a Phase 2 elezanumab study update in acute cervical spinal cord injury — relevant for pipeline upside but data are early and timing/impact remain uncertain. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Operational repositioning: coverage suggests AbbVie is reshaping U.S. operations with Medicaid concessions to prioritize growth categories — could ease payer tensions but may compress near-term margins. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus
• Negative Sentiment: AbbVie sued HHS over CMS selecting Botox for Medicare price cuts under the Inflation Reduction Act — the dispute highlights material regulatory risk to Botox revenue and creates legal uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Evercore ISI trimmed its price target modestly (while keeping Outperform), and broader analyst chatter highlights valuation/forecast risk — small downgrades can pressure sentiment after a rally. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Competitive pressure: heavy TV ad spending for J&J’s Tremfya (and continued promotion of rivals) raises marketing intensity in immunology, which could cap near‑term share gains for Rinvoq/Skyrizi. J&J’s Tremfya roars into 2026 with massive TV ad spend, trailed by AbbVie’s Rinvoq and Skyrizi

AbbVie Price Performance

Shares of NYSE ABBV opened at $220.74 on Thursday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a 50-day moving average of $223.47 and a 200 day moving average of $220.29. The stock has a market cap of $390.12 billion, a P/E ratio of 93.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ABBV shares. Raymond James Financial set a $256.00 target price on AbbVie in a research note on Monday, November 3rd. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Evercore reduced their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research report on Tuesday, November 4th. Finally, Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.